Real-World Studies
Abiraterone linked to shorter survival than enzalutamide in mCRPC cohort
George et alCancer Medicine

A real-world comparative effectiveness study evaluated overall survival (OS) and treatment patterns between abiraterone acetate and enzalutamide in patients with chemotherapy- and androgen receptor pathway inhibitor (ARPI)-naïve metastatic castration-resistant prostate cancer (mCRPC). Drawing from the Flatiron Health electronic health records (EHR) database between 2014 and 2023, the analysis included 2,731 patients (1,316 receiving abiraterone and 1,415 receiving enzalutamide) to address residual confounding and limitations common to administrative claims databases.
To balance baseline clinical characteristics, stabilized inverse probability treatment weighting (sIPTW) was utilized alongside Cox proportional hazards and Kaplan-Meier models. Across the overall cohort, abiraterone demonstrated significantly shorter sIPTW-adjusted median OS compared with enzalutamide (24.6 vs. 25.8 months; HR 1.13; 95% CI, 1.03–1.23; median follow-up of 21.8 and 23.2 months, respectively). Abiraterone was also associated with shorter treatment duration (7.9 vs. 9.5 months; HR 1.21; 95% CI, 1.11–1.31) and a shorter interval before initiating subsequent therapy (14.7 vs. 17.9 months; HR 1.20; 95% CI, 1.08–1.32).
In a dedicated subgroup analysis of 1,102 patients (40% of the cohort) who received first-line ARPI monotherapy without subsequent systemic treatment, outcomes remained unfavorable for abiraterone. In this subset, abiraterone treatment led to an sIPTW-adjusted median OS of 14.0 months compared to 17.7 months for enzalutamide (HR 1.32; 95% CI, 1.14–1.53) and shorter treatment duration (7.5 vs. 10.6 months; HR 1.30; 95% CI, 1.12–1.50). These granular EHR-based results confirm earlier claims database findings, showing that first-line abiraterone is associated with inferior real-world overall survival relative to enzalutamide in ARPI- and chemotherapy-naïve mCRPC despite earlier initiation of subsequent treatments.
Key Takeaways
- In chemotherapy- and ARPI-naïve mCRPC, first-line abiraterone was associated with significantly shorter sIPTW-adjusted overall survival compared with enzalutamide (median 24.6 vs. 25.8 months; HR 1.13; 95% CI, 1.03–1.23).
- First-line abiraterone resulted in shorter adjusted treatment duration (7.9 vs. 9.5 months; HR 1.21; 95% CI, 1.11–1.31) and shorter time to subsequent therapy (14.7 vs. 17.9 months; HR 1.20; 95% CI, 1.08–1.32) versus enzalutamide.
- Among the 40% of patients who received no subsequent systemic therapy, the survival disparity widened in favor of enzalutamide (median OS 14.0 vs. 17.7 months; HR 1.32; 95% CI, 1.14–1.53).
Read the original sourceCancer Medicine
